∙ Phase I only:

• A diagnosis of unresectable, recurrent, or metastatic DDLPS

• Measurable disease as defined by RECIST 1.1

∙ Phase II only:

• A diagnosis of unresectable, recurrent (e.g. recurrent retroperitoneal) or metastatic DDLPS

• Any number of prior lines of therapy

‣ Measurable disease and evidence of progression of disease as defined by RECIST 1.1 (including newly diagnosed disease, new disease sites in a patient who was previously NED, or a 20% growth of existing lesions within 6 months of registration)

⁃ Age ≥ 18 years

⁃ ECOG performance status ≤ 2

⁃ Adequate organ and marrow function as defined below (ULN indicates institutional upper limit of normal):

• Absolute neutrophil count ≥ 1.5 x 109/L

• Hemoglobin ≥ 9.0 g/dL

• Platelets ≥ 100 x 109/L

• Total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels \> 1.5 ULN, except patients with Gilbert's disease (≤3x ULN)

• AST (SGOT) /ALT (SGPT) ≤ 1.5 x institutional ULN

• Creatinine Clearance ≥ 60 mL/min (calculated by Cockcroft-Gault method)

‣ Adequate coagulation function, as determined by:

• International Normalized Ratio (INR) ≤ 1.5 × ULN (Grade ≤ 1). If the participant receives anticoagulant therapy, the INR \> 1.5 × ULN is permitted but the dose must be stable for at least 2 weeks before the start of the study treatments.

• PTT ≤ 1.5 × ULN.

‣ Adequate cardiac function, as determined by:

• Systolic blood pressure \< 160 mmHg and diastolic blood pressure \< 100 mmHg (Grade ≤ 2).

• LVEF ≥ 50% by MUGA or ECHO.

• No clinically significant ECG waveform abnormalities assessments at screening.

‣ Adequate glycemic control, as determined by:

• Fasting blood glucose level \< 125 mg/dL, or

• Random blood glucose level \< 200 mg/dL.

‣ Have normal serum calcium and phosphate levels (calcium level may be corrected for albumin level).

⁃ Have intraocular pressure ≤ 21 mmHg in both eyes

⁃ Women of child-bearing potential must agree to use highly effective contraceptive methods (hormonal or barrier method of birth control or abstinence) during the trial period through at least six months after the last dose. Male patients or their partners must be surgically sterile or agree to use adequate contraception while receiving trial treatment and for three months thereafter. Acceptable methods of contraceptive use by men or women are detailed in Section 15.3.

⁃ Ability to understand and the willingness to sign a written informed consent document.

⁃ Ability to swallow tablets or capsules

⁃ Patients with brain metastasis that have been treated with definitive surgery or radiation, and have been clinically stable for 3 months are eligible.